AAIPharma/Cambridge Major Labs to Relocate Analytical Testing Facility

February 19, 2016
BioPharm International Editors

AAIPharma/Cambridge Major Labs plans to invest $10.7 million to relocate the company’s analytical testing facility to the Cortex Innovation Center in Missouri.

AAIPharma Services Corp./Cambridge Major Laboratories, Inc. (AAI/CML), a provider of manufacturing and development services for the pharmaceutical and biotechnology industries, announced on Feb. 17, 2016 a planned investment of at least $10.7 million to relocate its St. Louis, MO analytical testing facility to the Cortex Innovation Center.

AAI/CML’s analytical testing business is comprised of three centers in St. Louis, MO; Wilmington, NC; and Edison, NJ. The company’s current St. Louis, MO facility specializes in chemical and microbiological analytical testing, including raw material testing, drug product release, stability, and environmental monitoring for both sterile and non-sterile drugs.

According to a press release from the company, the new facility will provide new testing capabilities, such as glass and plastic containers testing for pharmaceutical use, elemental impurities, disinfectant qualification, and efficacy studies. The structural completion and build-out are expected to be complete by the fourth quarter of 2016 and transition from the existing location will occur in the first quarter of 2017.

AAI/CML’s additional sites in Edison, NJ and Wilmington, NC will serve as testing support. AAI/CML will absorb the cost of method transfer exercises, reverifications or method suitabilities related to the site move, ensuring relevant regulatory requirements continue to be met. 

Source: AAI/CML

Related Content:

News | Supplier News